All In Biotech

Drug Trial Radar · NCT05093634

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Apr 26, 2022

Primary completion

Dec 19, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a) * Leptin receptor (LEPR; Sub-study 035b) * Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 \[SCR1\]; Sub-study 035c) * Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d) The objectives and endpoints are identical for these sub-studies.

Conditions

  • Obesity
  • Genetic Obesity

Interventions

  • SetmelanotideDrug

    Subcutaneous Injection

  • PlaceboDrug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)Time frame: Baseline, Week 52

Locations

66 sites in 10 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • HonorHealth Bariatric Center

    Scottsdale, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Yale Center for Clinical Investigation

    New Haven, Connecticut

  • Advent Health

    Altamonte Springs, Florida

  • University of Florida

    Gainesville, Florida

  • InQuest Medical Research

    Suwanee, Georgia

  • UMASS Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Metro Detroit Endocrinology Center

    Dearborn, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • St. Luke's Hospital

    Chesterfield, Missouri

  • Children's Mercy

    Kansas City, Missouri

  • Washington University in St. Louis

    St Louis, Missouri

  • University of Buffalo

    Buffalo, New York

  • Metropolitan Hospital Center

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • Columbia University

    New York, New York

  • Ten's Medical Center - Pediatric Endocrinology Clinic

    Staten Island, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Geisinger Clinic

    Danville, Pennsylvania

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UPMC Montefiore

    Pittsburgh, Pennsylvania

  • Vanderbilt University School of Medicine

    Nashville, Tennessee

  • Texas Tech

    Amarillo, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Biopharma Informatic

    Houston, Texas

  • Rio Grande Valley Endocrine Center

    McAllen, Texas

  • Endocrine Associates of Dallas and Plano

    Plano, Texas

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

  • West Virginia University

    Morgantown, West Virginia

  • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc

    Marshfield, Wisconsin

  • University of Alberta - Alberta Diabetes Institute (ADI)

    Edmonton, Alberta, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • GH Est Hopital Femme Mere Enfant

    Lyon, France

  • Hu Pitie Salpetriere Aphp

    Paris, France

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.